We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+4.37%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$338M
AUM Growth
-$1.49B
(-81%)
Cap. Flow
-$1.49B
Cap. Flow
% of AUM
-440.09%
Top 10 Holdings %
Top 10 Hldgs %
50.11%
Holding
82
New
26
Increased
20
Reduced
13
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$21.3M |
| 2 |
Integra LifeSciences
IART
|
+$13.4M |
| 3 |
AbbVie
ABBV
|
+$12.8M |
| 4 |
AdaptHealth
AHCO
|
+$9.39M |
| 5 |
Encompass Health
EHC
|
+$8.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$6.95M |
| 2 |
ICU Medical
ICUI
|
+$6.55M |
| 3 |
Labcorp
LH
|
+$6.3M |
| 4 |
Centene
CNC
|
+$5.94M |
| 5 |
SI-BONE Inc
SIBN
|
+$5.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.24% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
51
DELISTED
Sage Therapeutics
SAGE
| $1.44M | 0.43% |
+23,588
| New | +$1.2M |
|
52
Quince Therapeutics
QNCX
$29.5M
| $1.09M | 0.32% |
+109
| New | +$991K |
|
53
Baxter International
BAX
$14.2B
| $1.01M | 0.3% |
12,575
-29,864
| -70% | -$2.51M |
|
54
Axogen
AXGN
$2.5B
| $817K | 0.24% |
+70,209
| New | +$815K |
|
|
INBX
55
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $647K | 0.19% |
+35,935
| New | +$651K |
|
56
Pennant Group
PNTG
$1.36B
| $528K | 0.16% |
+13,699
| New | +$420K |
|
57
ADC Therapeutics
ADCT
$144M
| $396K | 0.12% |
12,000
+7,590
| +172% | +$329K |
|
|
RNTX
58
Rein Therapeutics
RNTX
$69.9M
| $340K | 0.1% |
+13,172
| New | +$310K |
|
59
Corbus Pharmaceuticals
CRBP
$190M
| $162K | 0.05% |
+2,996
| New | +$543K |
|
60
Becton Dickinson
BDX
$48.2B
| – | – |
-6,232
| Closed | -$1.46M |
|
61
Boston Scientific
BSX
$71.5B
| – | – |
-106,338
| Closed | -$3.73M |
|
|
HOLX
62
DELISTED
Hologic
HOLX
| – | – |
-81,789
| Closed | -$4.66M |
|
|
63
ICU Medical
ICUI
$4.61B
| – | – |
-35,556
| Closed | -$6.55M |
|
64
IQVIA
IQV
$39.3B
| – | – |
-15,773
| Closed | -$2.24M |
|
65
PUT
iShares Russell 2000 Value ETF
IWN
$14.6B
| – | – |
-108,600
| Closed | -$1.55B |
|
|
66
Labcorp
LH
$25.9B
| – | – |
-44,133
| Closed | -$6.3M |
|
|
67
Medtronic
MDT
$112B
| – | – |
-75,828
| Closed | -$6.95M |
|
68
Vaxcyte
PCVX
$8.64B
| – | – |
-6,827
| Closed | -$216K |
|
69
Insulet
PODD
$9.79B
| – | – |
-2,465
| Closed | -$479K |
|
70
PTC Therapeutics
PTCT
$6.12B
| – | – |
-19,677
| Closed | -$998K |
|
71
Sanofi
SNY
$104B
| – | – |
-99,869
| Closed | -$5.1M |
|
72
Universal Health Services
UHS
$10.5B
| – | – |
-24,178
| Closed | -$2.25M |
|
73
Dentsply Sirona
XRAY
$2.43B
| – | – |
-35,059
| Closed | -$1.54M |
|
|
TCRR
74
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| – | – |
-38,494
| Closed | -$591K |
|
|
HRC
75
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| – | – |
-35,604
| Closed | -$3.91M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Endurant Capital Management held 82 positions worth $338M, down 81% from $1.82B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Endurant Capital Management withdrew a net $1.49B in Q3 2020, closing 22 positions and reducing 13 holdings. Its most notable exit was Medtronic, an estimated $6.95M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 12% a quarter earlier, followed by Industrials.
Against the trend, Endurant Capital Management opened a new position in Integra LifeSciences worth $13.3M.
- Endurant Capital Management's largest Q3 2020 buy was Integra LifeSciences: 281,608 shares worth $13.3M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q3 2020, an estimated $21.3M increase.
- Endurant Capital Management's biggest Q3 2020 reduction was Centene, cutting an estimated $5.94M.
- Endurant Capital Management fully exited Medtronic in Q3 2020, selling an estimated $6.95M.
- Endurant Capital Management's ten largest holdings make up 50% of its $338M portfolio in Q3 2020.
- Endurant Capital Management opened 26 new positions and closed 22 in Q3 2020.
- Endurant Capital Management's portfolio value fell 81% quarter-over-quarter to $338M.
Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.